Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients

被引:39
作者
Mansouri, E
Blome-Eberwein, S
Gabelsberger, J
Germann, G
von Specht, BU
机构
[1] Surg Univ Hosp, D-79106 Freiburg, Germany
[2] Burn Ctr, Ludwigshafen, Germany
[3] MediGene AG, Planegg Martinsried, Germany
来源
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY | 2003年 / 37卷 / 2-3期
关键词
Pseudomonas aeruginosa; outer membrane protein; vaccine; burn; infectious disease;
D O I
10.1016/S0928-8244(03)00072-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In a recent clinical trial we evaluated the safety and immunogenicity of a recombinant OprF-OprI vaccine consisting of the mature outer membrane protein I (OprI) and amino acids 190-342 of OprF of Pseudomonas aeruginosa in burn patients and compared the elicited antibodies with antibodies against tetanus as response to a simultaneous immunization given on the day of admission. Safety and immunogenicity of the vaccine had been tested before in healthy human volunteers as published in 1999. In this first clinical trial we immunized eight burn patients suffering from second or third degree burns involving between 35% and 55% of the body surface three times with 100 mug of the OprF-OprI vaccine. The vaccine was found to be very well tolerated. The patients did not show any serious side effects - and in particular no activation of the mediator cascade was observed. None of the subjects showed systemic P. aeruginosa infections during or after the treatment of their burns. The serological tests (ELISA) for detection of antibodies against P. aeruginosa and tetanus toxoid showed seroconversion for seven patients after inoculation. The data indicate that OprF-OprI can be a useful vaccine in the therapeutic management of burn injuries. (C) 2003 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 28 条
[1]   IMMUNIZATION AGAINST PSEUDOMONAS IN INFECTION AFTER THERMAL INJURY [J].
ALEXANDE.JW ;
FISHER, MW .
JOURNAL OF INFECTIOUS DISEASES, 1974, 130 :S152-S158
[2]   NAKED DNA POINTS WAY TO VACCINES [J].
COHEN, J .
SCIENCE, 1993, 259 (5102) :1690-1692
[3]  
Donnelly J. J., 1994, IMMUNOLOGIST, V2, P20
[4]   Multi-drug resistant Pseudomonas aeruginosa outbreak in a burns unit -: an infection control study [J].
Douglas, MW ;
Mulholland, K ;
Denyer, V ;
Gottlieb, T .
BURNS, 2001, 27 (02) :131-135
[5]   SEQUENCE AND TRANSCRIPTIONAL START SITE OF THE PSEUDOMONAS-AERUGINOSA OUTER-MEMBRANE PORIN PROTEIN-F GENE [J].
DUCHENE, M ;
SCHWEIZER, A ;
LOTTSPEICH, F ;
KRAUSS, G ;
MARGET, M ;
VOGEL, K ;
VONSPECHT, BU ;
DOMDEY, H .
JOURNAL OF BACTERIOLOGY, 1988, 170 (01) :155-162
[6]  
DUCHENE M, 1989, J BACTERIOL, V171, P4130
[7]   PROTECTION OF IMMUNOSUPPRESSED MICE AGAINST INFECTION WITH PSEUDOMONAS-AERUGINOSA BY RECOMBINANT PSEUDOMONAS-AERUGINOSA LIPOPROTEIN-I AND LIPOPROTEIN-I-SPECIFIC MONOCLONAL-ANTIBODIES [J].
FINKE, M ;
MUTH, G ;
REICHHELM, T ;
THOMA, M ;
DUCHENE, M ;
HUNGERER, KD ;
DOMDEY, H ;
VONSPECHT, BU .
INFECTION AND IMMUNITY, 1991, 59 (04) :1251-1254
[8]   PROTECTION AGAINST EXPERIMENTAL PSEUDOMONAS-AERUGINOSA INFECTION BY RECOMBINANT PSEUDOMONAS-AERUGINOSA LIPOPROTEIN-I EXPRESSED IN ESCHERICHIA-COLI [J].
FINKE, M ;
DUCHENE, M ;
ECKHARDT, A ;
DOMDEY, H ;
VONSPECHT, BU .
INFECTION AND IMMUNITY, 1990, 58 (07) :2241-2244
[9]  
GABELSBERGER J, 1997, BEHRING I MITT, V98, P302
[10]   USE OF A PURIFIED OUTER-MEMBRANE PROTEIN-F (PORIN) PREPARATION OF PSEUDOMONAS-AERUGINOSA AS A PROTECTIVE VACCINE IN MICE [J].
GILLELAND, HE ;
PARKER, MG ;
MATTHEWS, JM ;
BERG, RD .
INFECTION AND IMMUNITY, 1984, 44 (01) :49-54